The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy

Cancer

Volumn 80, Issue 12, 1997, Pages 2240-2249

  Kinney, Anita Yeomans ^a,b,c   Sahin, Aysegul ^a   Vernon, Sally W ^b   Frankowski, Ralph F ^b   Annegers, John F ^b   Hortobagyi, Gabriel N ^a,e   Buzdar, Aman U ^a   Frye, Debra K ^a   Dhingra, Kapil ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B72.3 antibody; Breast carcinoma; Sialyl Tn antigen; Tumor biology

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLYCOSYLATED PROTEIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LEUCOVORIN; METHOTREXATE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 0031440754     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971215)80:12<2240::AID-CNCR4>3.0.CO;2-Y     Document Type: Article

References (62)

1. Ding L, Lalani E-N, Reddish M, Koganty R, Wong T, Samuel J, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17.
2. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of the human tumor-associated polymorphic epithelial mucin, PEM. J Biol Chem 1990;265:15286-93.
3. Jentoff N. Why are proteins O-glycosylated? Trends Biochem Sci 1990;15:291-4.
4. Parry G, Beck JC, Moss L, Varley J, Ojakian GK. Determination of apical membrane polarity in mammary epithelial cell cultures: the role of cell-cell substratum and membrane-cytoskeleton interactions. Exp Cell Res 1990;188:302-11.
5. Wong RCK, O'Donnell R, Vercelli D, Sancho J, Terhorst C, Rosen F, et al. Signal transduction via leukocyte antigen CD43 (sialophorin): feedback regulation by protein kinase C. J Immunol 1990;144:1455-60.
6. Mandel U, Petersen OW, Sorensen H, Vedtofte P, Hakomori S, Clausen H, et al. Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J Invest Dermatol 1991;977:713-21.
7. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty R, Reddish M, et al. Immune sera and monoclonal antibodies define low configurations for the sialyl Tn tumor antigen. Cancer Res 1995;55:3364-8.
8. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of gastrointestinal and pancreatic cancer - associated antigen detected by monoclonal antibody 19-9 in sera of patients as a mucin. Cancer Res 1983;43:5489-92.
9. Rittenhouse HG, Manderino GL, Hass GM. Mucin-type glycoproteins as tumor markers. Lab Med 1985;16:556-60.
10. Burchell J, Wang D, Taylor-Papadimitriou J. Detection of the tumor-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer 1984;34:763-8.
11. Price MR, Clarke AJ, Robertson JFR, O'Sullivan C, Baldwin RW, Blarney RW. Detection of polymorphic epithelial mucin in the serum of systemic breast cancer patients using the monoclonal antibody, NRC-11. Cancer Immunol Immunother 1990;31:269-72.
12. Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52: 257-331.
13. Hakomori S-I. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
14. Springer GF. General carcinoma autoantigens. Science 1984; 224:1198-1206.
15. Singhal A, Hakomori S. Molecular changes in carbohydrate antigens associated with cancer. Bioassays 1990;12:223-30.
16. Nuti M, Termoto YA, Mariani-Constantini R, Horan-Hand P, Colche D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;2:539-45.
17. Yurewicz EC, Matsura F, Moghissi KS. Structural studies of sialylated oligosaccharides of human midcycle cervical mucin. J Biol Chem 1987;262:4733-9.
18. Yonezawa S, Tachikawa T, Shin S, Sato E. Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas. Am J Clin Pathol 1992;98:167-74.
19. Reed W, Bryne M, Clausen H, Dabelsteen E, Nesland JM. Simple mucins (T, sialosyl-T, Tn and sialosyl-Tn) are not diagnostic for malignant breast lesions. Anticancer Res 1994;14:609-16.
20. Herlyn M, Sears HF, Steplewski A, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen: I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982;2: 135-44.
21. Metzgar RA, Rodriguez N, Finn OJ, Lan OS, Daasch VN, Fersten PD. Detection of a pancreatic cancer-associated antigen (DV-PAN-2) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A 1984;81:5242-6.
22. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, et al. Expression of Tn, sialosyl-Tn and T antigens in human colon cancer. Cancer Res 1989;49: 197-204.
23. Ohuchi N, Thor A, Nose M, Kyogoku M, Schlom J. Tumor associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. Int J Cancer 1989; 38:643-50.
24. Orntoft T, Harving N, Langkilde NC. O-linked mucin-type glycoproteins in normal and malignant colonic mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer 1993;45:666-72.
25. Bergeron C, Shatz P, Margolese R, Major P, Ferenczy A. Immunohistochemical studies with monoclonal antibodies B72.3 and MAS on histologic and cytologic specimens from benign and malignant breast lesions. Anal Quant Cytol Histol 1989;11:33-42.
26. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-24.
27. Cho SH, Sahin A, Hortobagyi GN, Hilttelman W, Dhingra K. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 1994;54:6302-5.
28. Contegiacomo A, Alimandi M, Muraro R, Pizzi C, Calderopoli R, DeMarchis L, et al. Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur J Cancer 1994;39A:813-20.
29. Miles DW, Happerfield LC, Smith P, Gillibrand R, Bobrow LG, Gregrory WM, et al. Expression of sialysl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994;70:1272-5.
30. Inou M, Ogawa H, Nakanishi K, Tanizawa O, Karino K, Endo J. Clinical value of sialyl-Tn antigen in patients with gynecologic tumors. Obstet Gynecol 1990;75:1032-6.
31. a antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer. Eur J Surg Oncol 1995;21:168-75.
32. Kakeji Y, Maehara Y, Morita M, Matsukuma A, Furusawa M, Takahashi I, et al. Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. Br J Cancer 1995;71:191-5.
33. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66: 1960-6.
34. Chun MAX, Terata N, Kodami M, Janic S, Hosokawa Y, Hattori T. Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur J Cancer 1993;29:1820-3.
35. Mooto Y, Kawakami H, Watanabe H, Satomura Y, Ohta H, Okai T, et al. Serum sialyl-Tn antigen levels in patients with digestive cancer. Oncology 1991;48:321-6.
36. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
37. Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic tumors. Cancer 1992;69: 2368-78.
38. Yamaguchi A, Tukioka Y, Fushida S, Kurosaka Y, Kanno M, Yonemura Y, et al. Serum sialyl-Tn antigen in colorectal cancer and its relationship to prognosis. Jpn J Cancer Chem 1992;19:349-58.
39. Black MM. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957;105:97-102.
40. Breslow NE, Day NE. Statistical methods in cancer research. Volume II. The design and analysis of cohort studies. London: Oxford University Press, 1987.
41. Cohen, J. A coefficient of agreement for nominal scales. Educ Psychol Measures 1960;20:37-46.
42. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
43. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958;53:457-81.
44. Cox DR, Oakes D. Analysis of survival data. New York: Chap man and Hall, 1984.
45. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic research. Am J Epidemiol 1995;142:1255-64.
46. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: J. B. Lippincott, 1992.
47. McGuire WL. Breast cancer prognostic guidelines: evaluation guidelines [editorial]. J Natl Cancer Inst 1991;83:254-5.
48. Hilsenbeck SG, Clark GM, McGuire, WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992;22:197-206.
49. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
50. Shin D, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:3153-9.
51. Vierbuchen MJ, Fruechtnicht W, Brackrock S, Krause KT, Zienkiewicz TJ. Quantitative lectinhistochemical and immunohistochemical studies on the occurrence of alpha (2,3)-and alpha (2,6)-linked sialic acid residues in colorectal carcinomas. Cancer 1995;76:727-35.
52. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997;45:327-43.
53. Brooks SA, Leathem AJC. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet 1991;338:71-4.
54. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, et al. Indium-111 - labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. Nucl Med 1991;32:1326-32.
55. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunol 1996;19:59-68.
56. neu. Oncogene 1994;9:3139-47.
57. Carraway KL, Hull SR. Cell surface mucin-type glycoproteins and mucin-like domains. Glycobiology 1991;1:131-8.
58. Bremer E, Rebbaa A, Schnaar R, Magnani J, Yamamoto H. NANA-Lac neoglycoproteins inhibit EGF receptor autophosphorylation by interaction with the external domain of the receptor [abstract]. Glycoconjugate J 1995;12:589.
59. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2(c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.
60. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. C-erB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994;330:1260-6.
61. Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinex-Maza O, Berek J. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogene. Cancer Res 1990;50:7364-70.
62. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992;52:4741-6.